Similar articles

Abstract: lynch syndrome (LS), an autosomal dominantly inherited disease previously known as hereditary non-polyposis colorectal cancer (HNPCC), leads to a high risk of colorectal cancer (CRC) as well as malignancy at certain sites including endometrium, ovary, stomach, and small bowel (Hampel et al., 2008; Lynch et al., 2009). Clinically, LS is considered the most common hereditary CRC-predisposing syndrome, accounting for about 3% of all CRC cases (Popat et al., 2005). LS is associated with mutations of DNA mismatch repair (MMR) genes such as MLH1, MSH2, MSH6, PMS2, and EPCAM (Ligtenberg et al., 2009; Lynch et al., 2009), which can trigger a high frequency of replication errors in both microsatellite regions and repetitive sequences in the coding regions of various cancer-related genes. Immunohistochemistry (IHC) tests followed by genetic analysis of these mutations play a significant role in diagnosis, treatment determination, and therapeutic response prediction of LS (Lynch et al., 2009; Alex et al., 2017; Ryan et al., 2017). Here, we report substitution of one base-pair in exon 1 of MLH3 (c.1397C>A) and a frameshift mutation in exon 19 of MLH1 (c.2250_2251ins AA) in a 43-year-old Chinese male with an LS pedigree.

一个中国Lynch综合征家系携带的MLH1基因第19号外显子移码突变:一项家系研究

[1]Alex AK, Siqueira S, Coudry R, et al., 2017. Response to chemotherapy and prognosis in metastatic colorectal cancer with DNA deficient mismatch repair. Clin Colorectal Cancer, 16(3):228-239.

[2]Chen PC, Dudley S, Hagen W, et al., 2005. Contributions by mutl homologues Mlh3 and Pms2 to DNA mismatch repair and tumor suppression in the mouse. Cancer Res, 65(19):8662-8670.

[3]Chen PC, Kuraguchi M, Velasquez J, et al., 2008. Novel roles for MLH3 deficiency and TLE6-like amplification in DNA mismatch repair-deficient gastrointestinal tumorigenesis and progression. PLoS Genet, 4(6):e1000092.

[4]Dominguez-Valentin M, Nilbert M, Wernhoff P, et al., 2013. Mutation spectrum in south american lynch syndrome families. Hered Cancer Clin Pract, 11(1):18.

[5]Hampel H, Frankel WL, Martin E, et al., 2008. Feasibility of screening for lynch syndrome among patients with colorectal cancer. J Clin Oncol, 26(35):5783-5788.

[6]Hienonen T, Laiho P, Salovaara R, et al., 2003. Little evidence for involvement of MLH3 in colorectal cancer predisposition. Int J Cancer, 106(2):292-296.

[7]Kim KH, Kim JY, Oh SI, et al., 2009. A novel germline mutation of hMLH1 in a korean hereditary non-polyposis colorectal cancer family. Int J Oncol, 34(5):1313-1318.

[8]Korhonen MK, Vuorenmaa E, Nyström M, 2008. The first functional study of MLH3 mutations found in cancer patients. Genes Chromosomes Cancer, 47(9):803-809.

[9]Ligtenberg MJL, Kuiper RP, Chan TL, et al., 2009. Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1. Nat Genet, 41(1):112-117.

[10]Lynch HT, Lynch PM, Lanspa SJ, et al., 2009. Review of the lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medicolegal ramifications. Clin Genet, 76(1):1-18.

[11]Mohd AB, Palama B, Nelson SE, et al., 2006. Truncation of the C-terminus of human MLH1 blocks intracellular stabilization of PMS2 and disrupts DNA mismatch repair. DNA Repair, 5(3):347-361.

[12]Popat S, Hubner R, Houlston RS, 2005. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol, 23(3):609-618.

[13]Ryan E, Sheahan K, Creavin B, et al., 2017. The current value of determining the mismatch repair status of colorectal cancer: a rationale for routine testing. Crit Rev Oncol Hematol, 116:38-57.

[14]Sheng JQ, Fu L, Sun ZQ, et al., 2008. Mismatch repair gene mutations in Chinese HNPCC patients. Cytogenet Genome Res, 122(1):22-27.

[15]List of electronic supplementary materials

[16]Fig. S1 Sequencing of the proband

[17]Fig. S2 Sequencing of the patients of the Lynch syndrome pedigree